http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Xiaoliang Dong (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Shuiyun Li,Yongshang Tian,Xiaoliang Dong,Peng Liu,Xiang Ji,Xiongjie Hu 한양대학교 세라믹연구소 2021 Journal of Ceramic Processing Research Vol.22 No.5
Ceramic proppants is crucial in hydraulic fracturing for increasing oil and gas reservoirs. In this study, the ceramic particlesand resin-impregnated ceramic particles were prepared with fly ash, and then ultra-lightweight ceramic particles (proppants)were obtained by double resin-coating process. Crystalline phase and microstructure of the ceramic particles were investigatedby X-ray diffraction (XRD) and scanning electron microscopy (SEM), respectively. Effects of silicon carbide and epoxy resinconcentrations on the phase, apparent density, and breakage ratio of the ceramic particles were all studied systematically. Withincreasing silicon carbide contents, the corundum phase transform to mullite phase, decreasing the apparent density andincreasing the breakage ratios. The double resin-coated ceramic proppants featured smoother surface and less pores than theresin-impregnated samples, accompanying low apparent density (1.94 g/cm-3) and high strength (breakage ratio under 52 MPa,1.69%) when silicon carbide was 3.0 wt.% and epoxy resin concentrations was 55 wt.%. The results suggest the particles bythe effective double resin-coating process possess promising candidates for fracturing proppants in practical applications.
-
Weiguang Gu,Hua Zhang,Yiyu Lu,Minjing Li,Shuang Yang,Jianmiao Liang,Zhijian Ye,Zhihua Li,Minhong He,Xiaoliang Shi,Fei Wang,Dong You,Weiquan Gu,Weineng Feng 대한암학회 2023 Cancer Research and Treatment Vol.55 No.3
Purpose We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations. Materials and Methods This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non–small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR–tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint. Results The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment. Conclusion EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
